2023 World Conference on Lung Cancer (Posters)-EP13.01. Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study

EP13.01. Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study - PDF(Abstract)

Back to course

Pdf Summary

In this study, the feasibility and clinical relevance of immunohistochemical (IHC) subtyping in Asian patients with small cell lung cancer (SCLC) was evaluated. The aim was to classify SCLC patients into molecular subtypes using IHC staining.<br /><br />A total of 60 samples from 52 patients were analyzed, with 47 samples from de novo SCLC and 9 samples from transformed SCLC. The expression of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, and YAP1) and conventional SCLC markers (synaptophysin, chromogranin A, and TTF-1) were measured.<br /><br />The results showed that ASCL1, NEUROD1, POU2F3, and YAP1 were expressed in 77.8%, 54.2%, 7%, and 3.5% of tumors, respectively. ASCL1 was the most common subtype, followed by NEUROD1. ASCL1 was also the predominant subtype in transformed SCLC cases. POU2F3 was positive in one case and co-expressed with ASCL1.<br /><br />The feasibility of molecular subtyping through IHC staining was confirmed in this study. However, larger studies are needed to validate the prognostic and therapeutic roles of this classification in SCLC patients.<br /><br />Overall, this study highlights the potential of IHC subtyping in identifying molecular subtypes of SCLC in Asian patients, which could have implications for prognosis and treatment decisions.

Asset Subtitle

Chi-Lu Chiang

Meta Tag

Speaker Chi-Lu Chiang

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

immunohistochemical subtyping

Asian patients

small cell lung cancer

IHC staining

molecular subtypes

SCLC subtype markers

conventional SCLC markers

ASCL1

NEUROD1

prognosis